

Martin Fañnacht

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/560274/publications.pdf>

Version: 2024-02-01

299
papers

22,960
citations

7568

77
h-index

10157

140
g-index

313
all docs

313
docs citations

313
times ranked

13908
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalized Management of Pheochromocytoma and Paraganglioma. <i>Endocrine Reviews</i> , 2022, 43, 199-239.	20.1	127
2	Reassessment of Postural Stimulation Testing as a Simple Tool to Identify a Subgroup of Patients With Unilateral Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e865-e873.	3.6	7
3	S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. <i>European Journal of Endocrinology</i> , 2022, 186, 25-36.	3.7	41
4	Plasma Steroid Profiling in Patients With Adrenal Incidentaloma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1181-e1192.	3.6	19
5	Adrenal wash-out CT: moderate diagnostic value in distinguishing benign from malignant adrenal masses. <i>European Journal of Endocrinology</i> , 2022, 186, 183-193.	3.7	20
6	Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors. <i>Annals of Internal Medicine</i> , 2022, 175, 325-334.	3.9	53
7	Liraglutide + PYY3-36 Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements. <i>Journal of Clinical Medicine</i> , 2022, 11, 753.	2.4	4
8	Impact of Lymphadenectomy on the Oncologic Outcome of Patients with Adrenocortical Carcinoma—A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 291.	3.7	10
9	Adrenal functional imaging. <i>Presse Medicale</i> , 2022, 51, 104114.	1.9	3
10	Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. <i>Endocrine-Related Cancer</i> , 2022, 29, 285-306.	3.1	12
11	Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using ⁶⁸ Ga-PentixaFor PET. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263693.	5.0	27
12	Transcriptome in paraffin samples for the diagnosis and prognosis of adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2022, 186, 607-617.	3.7	2
13	Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1348-e1355.	3.6	5
14	Roux-en-Y Gastric Bypass and Caloric Restriction but Not Gut Hormone-Based Treatments Profoundly Impact the Hypothalamic Transcriptome in Obese Rats. <i>Nutrients</i> , 2022, 14, 116.	4.1	5
15	Improved Diagnostic Accuracy of Clonidine Suppression Testing Using an Age-Related Cutoff for Plasma Normetanephrine. <i>Hypertension</i> , 2022, 79, 1257-1264.	2.7	8
16	Identification of predictive criteria for pathogenic variants of primary bilateral macronodular adrenal hyperplasia (PBMAH) gene <i>ARMC5</i> in 352 unselected patients. <i>European Journal of Endocrinology</i> , 2022, 187, 123-134.	3.7	18
17	Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 499-508.	11.4	55
18	Radiotherapy for Pediatric Adrenocortical Carcinoma – Review of the Literature. <i>Clinical and Translational Radiation Oncology</i> , 2022, , .	1.7	3

#	ARTICLE	IF	CITATIONS
19	FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma. <i>Endocrine</i> , 2022, 77, 411-418.	2.3	6
20	Differences in morbidity and mortality between unilateral adrenalectomy for adrenal Cushing's syndrome and bilateral adrenalectomy for therapy refractory extra-adrenal Cushing's syndrome. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 2481-2488.	1.9	3
21	ENDOCRINE TUMOURS: Our experience with the management of patients with non-metastatic adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2022, 187, R27-R40.	3.7	13
22	EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4596-4596.	1.6	4
23	Preanalytical Considerations and Outpatient Versus Inpatient Tests of Plasma Metanephrines to Diagnose Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3689-e3698.	3.6	4
24	Predictive Value of FDG Uptake in the Remaining Adrenal Gland Following Adrenalectomy for Adrenocortical Cancer. <i>Hormone and Metabolic Research</i> , 2021, 53, 24-31.	1.5	1
25	Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. <i>Human Pathology</i> , 2021, 110, 50-61.	2.0	18
26	Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation. <i>Science Advances</i> , 2021, 7, .	10.3	42
27	PKA C α subunit mutation triggers caspase-dependent Rl β subunit degradation via Ser ¹¹⁴ phosphorylation. <i>Science Advances</i> , 2021, 7, .	10.3	4
28	ENSAT registry-based randomized clinical trials for adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2021, 184, R51-R59.	3.7	11
29	Circulating microRNA Expression in Cushing's Syndrome. <i>Frontiers in Endocrinology</i> , 2021, 12, 620012.	3.5	11
30	First German Guideline on Diagnostics and Therapy of Clinically Non-Functioning Pituitary Tumors. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, 129, 250-264.	1.2	12
31	Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management. <i>Frontiers in Endocrinology</i> , 2021, 12, 643328.	3.5	12
32	Epithelial and Mesenchymal Markers in Adrenocortical Tissues: How Mesenchymal Are Adrenocortical Tissues?. <i>Cancers</i> , 2021, 13, 1736.	3.7	5
33	What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. <i>Journal of Personalized Medicine</i> , 2021, 11, 269.	2.5	14
34	Incidence of hyperkalemia during hypertonic saline test for the diagnosis of diabetes insipidus. <i>Endocrine Connections</i> , 2021, 10, 401-409.	1.9	2
35	Treatment of symptomatic hyponatremia with hypertonic saline: a real-life observational study. <i>European Journal of Endocrinology</i> , 2021, 184, 647-655.	3.7	19
36	Oxytocin Levels in Response to Pituitary Provocation Tests in Healthy Volunteers. <i>Journal of the Endocrine Society</i> , 2021, 5, A631-A631.	0.2	0

#	ARTICLE	IF	CITATIONS
37	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. <i>Nature Reviews Endocrinology</i> , 2021, 17, 435-444.	9.6	80
38	Method-Specific Cortisol and Dexamethasone Thresholds Increase Clinical Specificity of the Dexamethasone Suppression Test for Cushing Syndrome. <i>Clinical Chemistry</i> , 2021, 67, 998-1007.	3.2	18
39	A novel patient-derived cell line of adrenocortical carcinoma shows a pathogenic role of germline MUTYH mutation and high tumour mutational burden. <i>European Journal of Endocrinology</i> , 2021, 184, 823-835.	3.7	20
40	The role of regulated necrosis in endocrine diseases. <i>Nature Reviews Endocrinology</i> , 2021, 17, 497-510.	9.6	35
41	High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, , .	3.9	10
42	Mass spectrometry imaging identifies metabolic patterns associated with malignant potential in pheochromocytoma and paraganglioma. <i>European Journal of Endocrinology</i> , 2021, 185, 179-191.	3.7	12
43	Novel CYP11B-ligand [123/131]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, , 1.	6.4	7
44	Case Report: Consecutive Adrenal Cushingâ€™s Syndrome and Cushingâ€™s Disease in a Patient With Somatic CTNNB1, USP8, and NR3C1 Mutations. <i>Frontiers in Endocrinology</i> , 2021, 12, 731579.	3.5	5
45	FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale. <i>Frontiers in Endocrinology</i> , 2021, 12, 712107.	3.5	16
46	Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study. <i>British Journal of Cancer</i> , 2021, 125, 1233-1238.	6.4	14
47	Real world efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer. <i>Thyroid</i> , 2021, 31, 1531-1541.	4.5	11
48	Management of Patients With Glucocorticoid-Related Diseases and COVID-19. <i>Frontiers in Endocrinology</i> , 2021, 12, 705214.	3.5	15
49	Identifying New Potential Biomarkers in Adrenocortical Tumors Based on mRNA Expression Data Using Machine Learning. <i>Cancers</i> , 2021, 13, 4671.	3.7	12
50	Oxytocin levels in response to pituitary provocation tests in healthy volunteers. <i>European Journal of Endocrinology</i> , 2021, 185, 355-364.	3.7	5
51	Analysis of Telomere Maintenance Related Genes Reveals NOP10 as a New Metastatic-Risk Marker in Pheochromocytoma/Paraganglioma. <i>Cancers</i> , 2021, 13, 4758.	3.7	14
52	Plasma Metabolome Profiling for the Diagnosis of Catecholamine Producing Tumors. <i>Frontiers in Endocrinology</i> , 2021, 12, 722656.	3.5	7
53	Simulation-Based Interpretation of Therapeutically Monitored Cabozantinib Plasma Concentration in Advanced Adrenocortical Carcinoma with Hemodialysis. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 706-711.	2.0	0
54	Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS. <i>European Journal of Endocrinology</i> , 2021, 184, 167-178.	3.7	11

#	ARTICLE	IF	CITATIONS
55	Rationale and design of the cardiovascular status in patients with endogenous cortisol excess study (CV-CORT-EX): a prospective non-interventional follow-up study. BMC Endocrine Disorders, 2021, 21, 11.	2.2	2
56	Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma. Clinical Chemistry and Laboratory Medicine, 2021, 59, 353-363.	2.3	32
57	“Limited effects of bariatric surgery in patients with craniopharyngioma – bariatric surgery as a “neurosurgical” intervention?”. Adipositas - Ursachen Folgeerkrankungen Therapie, 2021, 15, .	0.2	0
58	Adrenocortical Carcinoma in Childhood: A Systematic Review. Cancers, 2021, 13, 5266.	3.7	12
59	The role of molecular profiling in adrenocortical carcinoma. Clinical Endocrinology, 2021, , .	2.4	4
60	Expression of the Chemokine Receptor CCR7 in the Normal Adrenal Gland and Adrenal Tumors and Its Correlation with Clinical Outcome in Adrenocortical Carcinoma. Cancers, 2021, 13, 5693.	3.7	1
61	Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications. Frontiers in Endocrinology, 2021, 12, 795116.	3.5	2
62	Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e307-e318.	3.6	45
63	Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1461-1468.	3.6	39
64	Response to Letter to the Editor: “CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma”. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3842-e3843.	3.6	0
65	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes and Endocrinology, the, 2020, 8, 773-781.	11.4	129
66	Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3295-3307.	3.6	34
67	RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4459-e4473.	3.6	24
68	Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma. Frontiers in Endocrinology, 2020, 11, 597878.	3.5	18
69	Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. , 2020, 8, e000469.		59
70	Next-generation therapies for adrenocortical carcinoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101434.	4.7	61
71	Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. Cell Death and Disease, 2020, 11, 192.	6.3	39
72	Cancer-testis Antigen FATE1 Expression in Adrenocortical Tumors Is Associated with A Pervasive Autoimmune Response and Is A Marker of Malignancy in Adult, but Not Children, ACC. Cancers, 2020, 12, 689.	3.7	14

#	ARTICLE	IF	CITATIONS
73	Early Postoperative Circulating miR-483-5p Is a Prognosis Marker for Adrenocortical Cancer. <i>Cancers</i> , 2020, 12, 724.	3.7	16
74	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3374-e3383.	3.6	17
75	Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. <i>Cancers</i> , 2020, 12, 359.	3.7	23
76	Bone Metastases in Medullary Thyroid Carcinoma: High Morbidity and Poor Prognosis Associated With Osteolytic Morphology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2239-e2246.	3.6	10
77	Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY3-36 Combination Therapy in Diet-Induced Obese Rats. <i>Frontiers in Endocrinology</i> , 2020, 11, 598843.	3.5	10
78	A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. <i>Investigational New Drugs</i> , 2020, 38, 1421-1429.	2.6	33
79	Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2642-2653.	3.6	18
80	Intratumor heterogeneity of prognostic DNA-based molecular markers in adrenocortical carcinoma. <i>Endocrine Connections</i> , 2020, 9, 705-714.	1.9	10
81	Clinical spectrum of primary adrenal lymphoma: results of a multicenter cohort study. <i>European Journal of Endocrinology</i> , 2020, 183, 453-462.	3.7	18
82	HIF2Î± supports pro-metastatic behavior in pheochromocytomas/paragangliomas. <i>Endocrine-Related Cancer</i> , 2020, 27, 625-640.	3.1	33
83	Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma. <i>Frontiers in Endocrinology</i> , 2019, 10, 487.	3.5	14
84	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 1440.	7.1	57
85	Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. <i>Lancet, The</i> , 2019, 394, 587-595.	13.7	97
86	Driver mutations in USP8 wild-type Cushingâ€™s disease. <i>Neuro-Oncology</i> , 2019, 21, 1273-1283.	1.2	65
87	Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22269-22274.	7.1	81
88	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. <i>Endocrinology</i> , 2019, 160, 2600-2617.	2.8	24
89	Prognostic Relevance of Steroid Sulfation in Adrenocortical Carcinoma Revealed by Molecular Phenotyping Using High-Resolution Mass Spectrometry Imaging. <i>Clinical Chemistry</i> , 2019, 65, 1276-1286.	3.2	19
90	Alterations in Protein Kinase A Substrate Specificity as a Potential Cause of Cushing Syndrome. <i>Endocrinology</i> , 2019, 160, 447-459.	2.8	32

#	ARTICLE	IF	CITATIONS
91	Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2535-2546.	3.6	29
92	GLP-1 and PYY3-36 reduce high-fat food preference additively after Roux-en-Y gastric bypass in diet-induced obese rats. Surgery for Obesity and Related Diseases, 2019, 15, 1483-1492.	1.2	20
93	Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3812-3820.	3.6	19
94	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2367-2374.	3.6	103
95	The Adrenal Gland: Central Relay in Health and Disease. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 81-83.	1.2	5
96	The New Genetic Landscape of Cushingâ€™s Disease: Deubiquitinases in the Spotlight. Cancers, 2019, 11, 1761.	3.7	27
97	Volumetric and texture analysis of pretherapeutic 18F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib. Endocrine, 2019, 63, 293-300.	2.3	13
98	CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 312-318.	3.6	96
99	Patterns of Lymph Node Recurrence in Adrenocortical Carcinoma: Possible Implications for Primary Surgical Treatment. Annals of Surgical Oncology, 2019, 26, 531-538.	1.5	22
100	Advanced Adrenocortical Carcinoma â€“ What to do when First-Line Therapy Fails?. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 109-116.	1.2	43
101	Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 578-584.	1.2	15
102	Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane. Molecular and Cellular Endocrinology, 2019, 480, 36-41.	3.2	8
103	Adrenomedullary function, obesity and permissive influences of catecholamines on body mass in patients with chromaffin cell tumours. International Journal of Obesity, 2019, 43, 263-275.	3.4	12
104	Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma. European Journal of Endocrinology, 2019, 180, 117-125.	3.7	59
105	The challenges of sodium measurements: indirect versus direct ion-selective method. European Journal of Endocrinology, 2019, 181, 193-199.	3.7	13
106	Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. European Journal of Endocrinology, 2019, 181, 409-420.	3.7	58
107	Metabolic impact of pheochromocytoma/paraganglioma: targeted metabolomics in patients before and after tumor removal. European Journal of Endocrinology, 2019, 181, 647-657.	3.7	19
108	OR29-2 Mild Autonomous Cortisol Excess (MACE) in Adrenal Incidentalomas - Metabolic Risk Profile and Urinary Steroid Metabolome Analysis in 1208 Prospectively Recruited Patients. Journal of the Endocrine Society, 2019, 3, .	0.2	0

#	ARTICLE	IF	CITATIONS
109	Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1686-1695.	3.6	105
110	Release and Decay Kinetics of Copeptin vs AVP in Response to Osmotic Alterations in Healthy Volunteers. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 505-513.	3.6	65
111	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension, 2018, 71, 317-325.	2.7	77
112	High-Resolution Tissue Mass Spectrometry Imaging Reveals a Refined Functional Anatomy of the Human Adult Adrenal Gland. Endocrinology, 2018, 159, 1511-1524.	2.8	37
113	Predictive Value of ¹⁸ F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib. Journal of Nuclear Medicine, 2018, 59, 756-761.	5.0	26
114	ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas. European Journal of Endocrinology, 2018, 178, 181-188.	3.7	15
115	Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4511-4523.	3.6	92
116	Impact of chronic hyponatremia on neurocognitive and neuromuscular function. European Journal of Clinical Investigation, 2018, 48, e13022.	3.4	27
117	A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus. New England Journal of Medicine, 2018, 379, 428-439.	27.0	180
118	European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. European Journal of Endocrinology, 2018, 179, G1-G46.	3.7	559
119	Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives. Endocrine, 2018, 62, 506-516.	2.3	11
120	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662.	2.4	45
121	Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. Clinical Chemistry, 2018, 64, 1646-1656.	3.2	121
122	Surviving ectopic Cushing's syndrome: quality of life, cardiovascular and metabolic outcomes in comparison to Cushing's disease during long-term follow-up. European Journal of Endocrinology, 2018, 179, 109-116.	3.7	24
123	Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging. Endocrine Connections, 2018, 7, 1168-1177.	1.9	11
124	FGF-21 levels in polyuria-polydipsia syndrome. Endocrine Connections, 2018, 7, 1501-1506.	1.9	0
125	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	16.8	532
126	Dosage-dependent regulation of VAV2 expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion. Science Signaling, 2017, 10, .	3.6	35

#	ARTICLE	IF	CITATIONS
127	Topoisomerase 2 α and thymidylate synthase expression in adrenocortical cancer. <i>Endocrine-Related Cancer</i> , 2017, 24, 319-327.	3.1	24
128	Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1358-1365.	3.6	108
129	Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. <i>European Journal of Endocrinology</i> , 2017, 177, 103-113.	3.7	82
130	Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1122-1132.	3.6	120
131	Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients. <i>Clinical Nuclear Medicine</i> , 2017, 42, e29-e34.	1.3	60
132	Cortisol-related metabolic alterations assessed by mass spectrometry assay in patients with Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2017, 177, 227-237.	3.7	23
133	Differential expression of the protein kinase A subunits in normal adrenal glands and adrenocortical adenomas. <i>Scientific Reports</i> , 2017, 7, 49.	3.3	17
134	Steroid Profiling for Adrenocortical Disorders: A Pathway for Omics-Based Diagnostics. <i>Clinical Chemistry</i> , 2017, 63, 1787-1789.	3.2	8
135	Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4323-4332.	3.6	79
136	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3491-3498.	3.6	33
137	PheoSeq. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 575-588.	2.8	63
138	Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study. <i>BMC Cancer</i> , 2017, 17, 522.	2.6	29
139	Livin/BIRC7 expression as malignancy marker in adrenocortical tumors. <i>Oncotarget</i> , 2017, 8, 9323-9338.	1.8	27
140	Laparoskopische Adrenalectomie. , 2017, , 187-195.		0
141	Inhibition of Cholesterol Esterification in the Adrenal Gland by ATR101/PD132301 α 2, A Promising Case of Drug Repurposing. <i>Endocrinology</i> , 2016, 157, 1719-1721.	2.8	5
142	Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. <i>European Journal of Endocrinology</i> , 2016, 175, G1-G34.	3.7	1,173
143	DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 102, jc.2016-3205.	3.6	44
144	Expression of 11 β -hydroxysteroid-dehydrogenase type 2 in human thymus. <i>Steroids</i> , 2016, 110, 35-40.	1.8	6

#	ARTICLE	IF	CITATIONS
145	Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using 18F-FDG positron emission tomography. <i>Endocrine</i> , 2016, 53, 791-800.	2.3	8
146	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. <i>Cancer Cell</i> , 2016, 29, 723-736.	16.8	482
147	MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2016, 175, R51-R64.	3.7	171
148	<scp>FATE</scp> 1 antagonizes calciumâ€•and drugâ€•induced apoptosis by uncoupling <scp>ER</scp> and mitochondria. <i>EMBO Reports</i> , 2016, 17, 1264-1280.	4.5	102
149	Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma. <i>Endocrine-Related Cancer</i> , 2016, 23, 825-837.	3.1	17
150	DIAGNOSIS OF ENDOCRINE DISEASE: The diagnostic performance of adrenal biopsy: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2016, 175, R65-R80.	3.7	97
151	Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. <i>Hormones and Cancer</i> , 2016, 7, 345-355.	4.9	12
152	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3526-3538.	3.6	65
153	The impact of external social and internal personal forces on consumersâ€™ brand community engagement on Facebook. <i>Journal of Product and Brand Management</i> , 2016, 25, 409-423.	4.3	70
154	Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. <i>European Journal of Endocrinology</i> , 2016, 175, 521-529.	3.7	90
155	Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide. <i>Hormones and Cancer</i> , 2016, 7, 211-218.	4.9	16
156	Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2016, 174, 343-353.	3.7	20
157	Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. <i>European Journal of Endocrinology</i> , 2016, 174, 363-372.	3.7	100
158	High evening salivary cortisol is an independent predictor of increased mortality risk in patients with systolic heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 69-73.	1.7	22
159	Consumer response to online/offline price differentiation. <i>Journal of Retailing and Consumer Services</i> , 2016, 28, 137-148.	9.4	56
160	Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas. <i>Journal of Clinical Investigation</i> , 2016, 126, 3383-3388.	8.2	66
161	Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas. <i>PLoS ONE</i> , 2016, 11, e0169009.	2.5	7
162	Dyslipidemia causes overestimation of plasma mitotane measurements. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, 150135.	0.5	3

#	ARTICLE	IF	CITATIONS
163	The Treatment of Well-Differentiated Thyroid Carcinoma. Deutsches Ärztblatt International, 2015, 112, 452-8.	0.9	40
164	Lack of utility of SDHB mutation testing in adrenergic metastatic pheochromocytoma. European Journal of Endocrinology, 2015, 172, 89-95.	3.7	17
165	Frequency and Clinical Correlates of Somatic Ying Yang 1 Mutations in Sporadic Insulinomas. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E776-E782.	3.6	42
166	Pregnancy in Women Previously Treated for an Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4604-4611.	3.6	19
167	Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 841-849.	3.6	274
168	Prognostic Value of Aldosterone and Cortisol in Patients Hospitalized for Acutely Decompensated Chronic Heart Failure With and Without Mineralocorticoid Receptor Antagonism. Journal of Cardiac Failure, 2015, 21, 208-216.	1.7	17
169	High Incidence of Adrenal Crisis in Educated Patients With Chronic Adrenal Insufficiency: A Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 407-416.	3.6	308
170	Expression of <sc>LIN</sc>28 and its regulatory micro<sc>RNA</sc>s in adult adrenocortical cancer. Clinical Endocrinology, 2015, 82, 481-488.	2.4	25
171	Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma. European Journal of Endocrinology, 2015, 172, 251-260.	3.7	47
172	Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. European Journal of Endocrinology, 2015, 172, 415-422.	3.7	43
173	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncology, The, 2015, 16, 426-435.	10.7	272
174	The New Molecular Landscape of Cushing's Disease. Trends in Endocrinology and Metabolism, 2015, 26, 573-583.	7.1	26
175	Treatment of malignant pheochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature. Clinical Endocrinology, 2015, 82, 84-90.	2.4	21
176	Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. Endocrine-Related Cancer, 2015, 22, 877-887.	3.1	58
177	Decoding the genetic basis of Cushing's disease: USP8 in the spotlight. European Journal of Endocrinology, 2015, 173, M73-M83.	3.7	46
178	Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome. Endocrine-Related Cancer, 2015, 22, 531-543.	3.1	27
179	Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. Endocrinology, 2015, 156, 3895-3908.	2.8	153
180	Selling luxury goods online: effects of online accessibility and price display. International Journal of Retail and Distribution Management, 2015, 43, 1065-1082.	4.7	30

#	ARTICLE	IF	CITATIONS
181	Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors. <i>Hormones and Cancer</i> , 2015, 6, 225-236.	4.9	8
182	A case report of a solitary pancreatic metastasis of an adrenocortical carcinoma. <i>BMC Surgery</i> , 2015, 15, 93.	1.3	3
183	Mutations in the deubiquitinase gene USP8 cause Cushing's disease. <i>Nature Genetics</i> , 2015, 47, 31-38.	21.4	450
184	Hypertension and hypertensive cardiomyopathy in patients with a relapse-free history of pheochromocytoma. <i>Clinical Endocrinology</i> , 2015, 82, 188-196.	2.4	5
185	Abstract 2976: Comprehensive Pan-Genomic characterization of adrenocortical carcinoma. , 2015, , .		2
186	ATR-101 phase 1 clinical study for adrenocortical carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4585-TPS4585.	1.6	3
187	Inducible Knock-Down of the Mineralocorticoid Receptor in Mice Disturbs Regulation of the Renin-Angiotensin-Aldosterone System and Attenuates Heart Failure Induced by Pressure Overload. <i>PLoS ONE</i> , 2015, 10, e0143954.	2.5	12
188	CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma. <i>PLoS ONE</i> , 2014, 9, e105855.	2.5	41
189	Novel Somatic Mutations in the Catalytic Subunit of the Protein Kinase A as a Cause of Adrenal Cushing's Syndrome: A European Multicentric Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2093-E2100.	3.6	92
190	PKA catalytic subunit mutations in adrenocortical Cushing's adenoma impair association with the regulatory subunit. <i>Nature Communications</i> , 2014, 5, 5680.	12.8	63
191	Extending downward is not always bad: Parent brand evaluations after brand extension to higher and lower price and quality levels. <i>Journal of Brand Management</i> , 2014, 21, 303-324.	3.5	23
192	EJE PRIZE 2014: Current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go?. <i>European Journal of Endocrinology</i> , 2014, 171, R1-R11.	3.7	37
193	Less common genotype variants of TP53 polymorphisms are associated with poor outcome in adult patients with adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2014, 170, 707-717.	3.7	8
194	Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer. <i>European Urology</i> , 2014, 65, 832-838.	1.9	121
195	Does bariatric surgery change olfactory perception? Results of the early postoperative course. <i>International Journal of Colorectal Disease</i> , 2014, 29, 253-260.	2.2	23
196	Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine. <i>Annals of Clinical Biochemistry</i> , 2014, 51, 38-46.	1.6	26
197	A Copeptin-Based Classification of the Osmoregulatory Defects in the Syndrome of Inappropriate Antidiuresis. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2376-2383.	6.1	62
198	Integrated genomic characterization of adrenocortical carcinoma. <i>Nature Genetics</i> , 2014, 46, 607-612.	21.4	560

#	ARTICLE	IF	CITATIONS
199	Constitutive Activation of PKA Catalytic Subunit in Adrenal Cushing's Syndrome. New England Journal of Medicine, 2014, 370, 1019-1028.	27.0	355
200	Adrenal Function After Adrenalectomy for Subclinical Hypercortisolism and Cushing's Syndrome: A Systematic Review of the Literature. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2637-2645.	3.6	99
201	No endogenous ouabain is detectable in human plasma by ultra-sensitive UPLC-MS/MS. Clinica Chimica Acta, 2014, 431, 87-92.	1.1	58
202	Thyroid Function, Cardiovascular Events, and Mortality in Diabetic Hemodialysis Patients. American Journal of Kidney Diseases, 2014, 63, 988-996.	1.9	57
203	International randomized, double-blind, placebo-controlled, phase 3 study of linsitinib (OSI-906, L) in patients (pts) with locally advanced or metastatic adrenocortical carcinoma (ACC).. Journal of Clinical Oncology, 2014, 32, 4507-4507.	1.6	1
204	Safety and tolerability of sorafenib for treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC): Detailed analyses from the phase III DECISION trial.. Journal of Clinical Oncology, 2014, 32, 6062-6062.	1.6	4
205	Prognostic factors of overall survival of stage III or IV adrenocortical carcinomas (ACC): A multicenter ENS@T study.. Journal of Clinical Oncology, 2014, 32, 4106-4106.	1.6	0
206	Abstract LB-182: Constitutive activation of PRKACA in adrenal Cushing's syndrome. , 2014, , .		0
207	Update in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4551-4564.	3.6	346
208	Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5 α -Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 161-171.	3.6	131
209	Simultaneous liquid chromatography tandem mass spectrometric determination of urinary free metanephrines and catecholamines, with comparisons of free and deconjugated metabolites. Clinica Chimica Acta, 2013, 418, 50-58.	1.1	82
210	Bariatric surgery for morbid obesity in craniopharyngioma. Clinical Endocrinology, 2013, 78, 385-390.	2.4	37
211	Functional Characterization of Adrenal Lesions Using [123I]IMTO-SPECT/CT. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1508-1518.	3.6	47
212	Prognostic impact of subclinical thyroid dysfunction in heart failure. International Journal of Cardiology, 2013, 168, 300-305.	1.7	57
213	[123I]Iodometomidate Imaging in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2755-2764.	3.6	45
214	Luxury web atmospherics: an examination of homepage design. International Journal of Retail and Distribution Management, 2013, 41, 901-916.	4.7	32
215	The Role of Surgery in the Management of Recurrent Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 181-191.	3.6	132
216	Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients. European Heart Journal, 2013, 34, 578-587.	2.2	46

#	ARTICLE	IF	CITATIONS
217	Reply to Letter. <i>Annals of Surgery</i> , 2013, 257, e15.	4.2	2
218	Single Nucleotide Polymorphism Array Profiling of Adrenocortical Tumors - Evidence for an Adenoma Carcinoma Sequence?. <i>PLoS ONE</i> , 2013, 8, e73959.	2.5	58
219	[131I]Iodometomidate for Targeted Radionuclide Therapy of Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 914-922.	3.6	70
220	Ribonucleotide Reductase Large Subunit (<i>RRM1</i>) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 3452-3461.	7.0	64
221	Low SGK1 Expression in Human Adrenocortical Tumors Is Associated with ACTH-Independent Glucocorticoid Secretion and Poor Prognosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E2251-E2260.	3.6	38
222	Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3495-3503.	3.6	146
223	<i>TP53</i> Germline Mutations in Adult Patients with Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E476-E485.	3.6	89
224	Combination Chemotherapy in Advanced Adrenocortical Carcinoma. <i>New England Journal of Medicine</i> , 2012, 366, 2189-2197.	27.0	692
225	Impact of Lymphadenectomy on the Oncologic Outcome of Patients With Adrenocortical Carcinoma. <i>Annals of Surgery</i> , 2012, 255, 363-369.	4.2	146
226	Single Nucleotide Polymorphism Microarray Analysis in Cortisol-Secreting Adrenocortical Adenomas Identifies New Candidate Genes and Pathways. <i>Neoplasia</i> , 2012, 14, 206-IN13.	5.3	31
227	Adrenal Cancer: Scientific Advances. <i>Molecular and Cellular Endocrinology</i> , 2012, 351, 1.	3.2	2
228	Clinical impact of TP53 alterations in adrenocortical carcinomas. <i>Langenbeck's Archives of Surgery</i> , 2012, 397, 209-216.	1.9	39
229	Adrenocortical carcinoma: a clinician's update. <i>Nature Reviews Endocrinology</i> , 2011, 7, 323-335.	9.6	336
230	Sunitinib inhibits cell proliferation and alters steroidogenesis by down-regulation of HSD3B2 in adrenocortical carcinoma cells. <i>Frontiers in Endocrinology</i> , 2011, 2, 27.	3.5	29
231	Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. <i>Clinical Endocrinology</i> , 2011, 75, 585-591.	2.4	110
232	Contemporary Management of Adrenocortical Carcinoma. <i>European Urology</i> , 2011, 60, 1055-1065.	1.9	92
233	Metastatic Adrenocortical Carcinoma: Results of 56 Pulmonary Metastasectomies in 24 Patients. <i>Annals of Thoracic Surgery</i> , 2011, 92, 1965-1970.	1.3	37
234	Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. <i>Human Mutation</i> , 2011, 32, 51-58.	2.5	117

#	ARTICLE	IF	CITATIONS
235	Plasma Concentrations of o,pâ€²DDD, o,pâ€²DDA, and o,pâ€²DDE as Predictors of Tumor Response to Mitotane in Adrenocortical Carcinoma: Results of a Retrospective ENS@T Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1844-1851.	3.6	160
236	Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3775-3784.	3.6	369
237	Î²-Catenin Activation Is Associated with Specific Clinical and Pathologic Characteristics and a Poor Outcome in Adrenocortical Carcinoma. Clinical Cancer Research, 2011, 17, 328-336.	7.0	128
238	Long-term effects of radiotherapy on cardiovascular risk factors in acromegaly. European Journal of Endocrinology, 2011, 164, 675-684.	3.7	6
239	T Cell Development Critically Depends on Prethymic Stromal Patched Expression. Journal of Immunology, 2011, 186, 3383-3391.	0.8	15
240	Copeptin in the Differential Diagnosis of the Polydipsia-Polyuria Syndromeâ€”Revisiting the Direct and Indirect Water Deprivation Tests. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1506-1515.	3.6	147
241	Influence of Short-Term Glucocorticoid Therapy on Regulatory T Cells In Vivo. PLoS ONE, 2011, 6, e24345.	2.5	46
242	Recent advances in the diagnosis and treatment of adrenocortical carcinoma. Regulatory Peptides, 2010, 164, 2.	1.9	0
243	Laparoscopic Versus Open Adrenalectomy for Adrenocortical Carcinoma: Surgical and Oncologic Outcome in 152 Patients. European Urology, 2010, 58, 609-615.	1.9	246
244	Reply to Sebastien Gaujoux, Stephane Bonnet, Bertrand Doussetâ€™s Letter to the Editor re: David Brix, Bruno Allolio, Wiebke Fenske, et al. Laparoscopic Versus Open Adrenalectomy for Adrenocortical Carcinoma: Surgical and Oncologic Outcome in 152 Patients. Eur Urol 2010;58:609â€”15. European Urology, 2010, 58, e54.	1.9	0
245	Assessment of serumâ€™free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clinical Endocrinology, 2010, 72, 305-311.	2.4	30
246	What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?. Clinical Endocrinology, 2010, 73, 561-565.	2.4	40
247	Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. European Journal of Endocrinology, 2010, 162, 349-356.	3.7	119
248	Adjuvant Therapy in Patients With Adrenocortical Carcinoma: A Position of an International Panel. Journal of Clinical Oncology, 2010, 28, e401-e402.	1.6	95
249	Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. European Journal of Endocrinology, 2010, 162, 597-602.	3.7	274
250	Improved Survival in Patients with Stage II Adrenocortical Carcinoma Followed Up Prospectively by Specialized Centers. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4925-4932.	3.6	150
251	Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Modern Pathology, 2010, 23, 1596-1604.	5.5	46
252	High Diagnostic and Prognostic Value of Steroidogenic Factor-1 Expression in Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E161-E171.	3.6	196

#	ARTICLE	IF	CITATIONS
253	Deficits in the Management of Patients With Adrenocortical Carcinoma in Germany. Deutsches Ärztblatt International, 2010, 107, 885-91.	0.9	44
254	Frequent incidental discovery of pheochromocytoma: data from a German cohort of 201 pheochromocytoma. European Journal of Endocrinology, 2009, 161, 355-361.	3.7	174
255	Clinical Predictors and Algorithm for the Genetic Diagnosis of Pheochromocytoma Patients. Clinical Cancer Research, 2009, 15, 6378-6385.	7.0	160
256	Potency and Tolerance of Calcitonin Stimulation with High-Dose Calcium<i>Versus</i>Pentagastrin in Normal Adults. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2970-2974.	3.6	82
257	Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocrine-Related Cancer, 2009, 16, 919-928.	3.1	71
258	Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocrine-Related Cancer, 2009, 16, 907-918.	3.1	63
259	New targets and therapeutic approaches for endocrine malignanciesâ†. , 2009, 123, 117-141.		97
260	Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma. Cancer, 2009, 115, 243-250.	4.1	597
261	Radiotherapy in adrenocortical carcinoma. Cancer, 2009, 115, 2816-2823.	4.1	165
262	Reply to Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma. Cancer, 2009, 115, 5848-5848.	4.1	5
263	Osteopontin stimulates invasion of NCIâ€h295 cells but is not associated with survival in adrenocortical carcinoma. Journal of Pathology, 2009, 218, 232-240.	4.5	13
264	Clinical management of adrenocortical carcinoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 273-289.	4.7	272
265	LONG-TERM OUTCOME OF LAPAROSCOPIC VERSUS OPEN ADRENALECTOMY FOR ADRENOCORTICAL CANCER. Journal of Urology, 2009, 181, 10-11.	0.4	0
266	Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2057-2062.	3.6	141
267	Silencing of the Mineralocorticoid Receptor by Ribonucleic Acid Interference in Transgenic Rats Disrupts Endocrine Homeostasis. Molecular Endocrinology, 2008, 22, 1304-1311.	3.7	13
268	Side Population Does Not Define Stem Cell-Like Cancer Cells in the Adrenocortical Carcinoma Cell Line NCI h295R. Endocrinology, 2008, 149, 1314-1322.	2.8	47
269	[123I]Iodometomidate for Molecular Imaging of Adrenocortical Cytochrome P450 Family 11B Enzymes. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2358-2365.	3.6	88
270	Impaired Subjective Health Status in 256 Patients with Adrenal Insufficiency on Standard Therapy Based on Cross-Sectional Analysis. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3912-3922.	3.6	242

#	ARTICLE	IF	CITATIONS
271	Vaccination against the Forkhead Family Transcription Factor Foxp3 Enhances Tumor Immunity. Cancer Research, 2007, 67, 371-380.	0.9	140
272	Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. New England Journal of Medicine, 2007, 356, 2372-2380.	27.0	679
273	Consequences of Web-based service quality: Uncovering a multi-faceted chain of effects. Journal of Interactive Marketing, 2007, 21, 35-54.	6.2	108
274	Quality of Electronic Services. Journal of Service Research, 2006, 9, 19-37.	12.2	420
275	Adrenocortical Carcinoma: Clinical Update. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2027-2037.	3.6	683
276	Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma. Clinical Endocrinology, 2006, 65, 215-222.	2.4	24
277	Intraoperative haemodynamic stability in patients with phaeochromocytoma ? minimally invasive vs conventional open surgery. Clinical Endocrinology, 2006, 65, 352-358.	2.4	28
278	A Dangerous Liaisonâ€”Pheochromocytoma in Patients with Malignant Disease. Annals of Surgical Oncology, 2006, 13, 1696-1701.	1.5	15
279	Comprehensive Mutation Scanning of NF1 in Apparently Sporadic Cases of Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3478-3481.	3.6	53
280	Efficacy of Adjuvant Radiotherapy of the Tumor Bed on Local Recurrence of Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4501-4504.	3.6	224
281	Peripheral administration of the N-terminal pro-opiomelanocortin fragment 1â€“28 to Pomcâˆ“/âˆ“ mice reduces food intake and weight but does not affect adrenal growth or corticosterone production. Journal of Endocrinology, 2006, 190, 515-525.	2.6	29
282	Induction of CD4+ and CD8+ T-Cell Responses to the Human Stromal Antigen, Fibroblast Activation Protein: Implication for Cancer Immunotherapy. Clinical Cancer Research, 2005, 11, 5566-5571.	7.0	62
283	Evidence against a role of human airway trypsin-like protease â€“ the human analogue of the growth-promoting rat adrenal secretory protease â€“ in adrenal tumourigenesis. European Journal of Endocrinology, 2005, 152, 143-153.	3.7	17
284	AKT Is Highly Phosphorylated in Pheochromocytomas But Not in Benign Adrenocortical Tumors. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4366-4370.	3.6	43
285	Peroxisome Proliferator-Activated Receptor-Î³ Agonists Suppress Adrenocortical Tumor Cell Proliferation and Induce Differentiation. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3886-3896.	3.6	67
286	Congenital Isolated Adrenocorticotropin Deficiency: An Underestimated Cause of Neonatal Death, Explained byTPITGene Mutations. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1323-1331.	3.6	116
287	Tumor Immunotherapy Targeting Fibroblast Activation Protein, a Product Expressed in Tumor-Associated Fibroblasts. Cancer Research, 2005, 65, 11156-11163.	0.9	148
288	The Adrenal Secretory Serine Protease AsP Is a Short Secretory Isoform of the Transmembrane Airway Trypsin-Like Protease. Endocrinology, 2004, 145, 1898-1905.	2.8	30

#	ARTICLE	IF	CITATIONS
289	Management of adrenocortical carcinoma. <i>Clinical Endocrinology</i> , 2004, 60, 273-287.	2.4	185
290	The pro-opiomelanocortin gene of the zebrafish (<i>Danio rerio</i>). <i>Biochemical and Biophysical Research Communications</i> , 2003, 303, 1121-1128.	2.1	47
291	Beyond Adrenal and Ovarian Androgen Generation: Increased Peripheral 5 α -Reductase Activity in Women with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2760-2766.	3.6	140
292	N-Terminal Proopiomelanocortin Acts as a Mitogen in Adrenocortical Tumor Cells and Decreases Adrenal Steroidogenesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2171-2179.	3.6	64
293	Service Orientation of a Retailer's Business Strategy: Dimensions, Antecedents, and Performance Outcomes. <i>Journal of Marketing</i> , 2002, 66, 86-101.	11.3	388
294	Angiotensin II type 1 receptor and ACTH receptor expression in human adrenocortical neoplasms. <i>Clinical Endocrinology</i> , 2001, 54, 627-632.	2.4	37
295	Octreotide LAR [®] treatment throughout pregnancy in an acromegalic woman. <i>Clinical Endocrinology</i> , 2001, 55, 411-415.	2.4	83
296	Dehydroepiandrosterone Replacement in Women with Adrenal Insufficiency: Effects on Body Composition, Serum Leptin, Bone Turnover, and Exercise Capacity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1968-1972.	3.6	88
297	Dehydroepiandrosterone Replacement in Women with Adrenal Insufficiency: Effects on Body Composition, Serum Leptin, Bone Turnover, and Exercise Capacity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1968-1972.	3.6	37
298	Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. <i>Endocrine Abstracts</i> , 0, , .	0.0	1
299	Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	5